AzurRx BioPharma Stock Forecast, Price & News

+0.07 (+2.03 %)
(As of 09/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume810,725 shs
Average Volume628,700 shs
Market Capitalization$32.83 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AzurRx BioPharma logo

About AzurRx BioPharma

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.79 out of 5 stars

Medical Sector

785th out of 1,352 stocks

Pharmaceutical Preparations Industry

385th out of 665 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

Is AzurRx BioPharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AzurRx BioPharma stock.
View analyst ratings for AzurRx BioPharma
or view top-rated stocks.

What stocks does MarketBeat like better than AzurRx BioPharma?

Wall Street analysts have given AzurRx BioPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AzurRx BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AzurRx BioPharma?

AzurRx BioPharma saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,540,000 shares, an increase of 43.9% from the August 15th total of 1,070,000 shares. Based on an average daily volume of 3,910,000 shares, the short-interest ratio is currently 0.4 days.
View AzurRx BioPharma's Short Interest

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for AzurRx BioPharma

How has AzurRx BioPharma's stock been impacted by Coronavirus?

AzurRx BioPharma's stock was trading at $6.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AZRX shares have decreased by 42.8% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19

When did AzurRx BioPharma's stock split? How did AzurRx BioPharma's stock split work?

Shares of AzurRx BioPharma reverse split before market open on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of AzurRx BioPharma stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AZRX?

4 brokerages have issued 1 year target prices for AzurRx BioPharma's stock. Their forecasts range from $20.00 to $50.00. On average, they expect AzurRx BioPharma's share price to reach $33.33 in the next year. This suggests a possible upside of 847.0% from the stock's current price.
View analysts' price targets for AzurRx BioPharma
or view top-rated stocks among Wall Street analysts.

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the following people:
  • James E. Sapirstein, Chairman, President & Chief Executive Officer
  • Daniel H. Schneiderman, Chief Financial Officer
  • James E. Pennington, Chief Medical Officer
  • Tony Baca, Vice President-Clinical Operations
  • Martin Krusin, Senior Vice President-Corporate Development

Who are some of AzurRx BioPharma's key competitors?

What other stocks do shareholders of AzurRx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

Who are AzurRx BioPharma's major shareholders?

AzurRx BioPharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.14%), Bank of New York Mellon Corp (0.93%), Geode Capital Management LLC (0.46%), Renaissance Technologies LLC (0.19%), Citadel Advisors LLC (0.18%) and Northern Trust Corp (0.13%).
View institutional ownership trends for AzurRx BioPharma

Which major investors are buying AzurRx BioPharma stock?

AZRX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of New York Mellon Corp, Geode Capital Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Goldman Sachs Group Inc., State Street Corp, and Northern Trust Corp.
View insider buying and selling activity for AzurRx BioPharma
or or view top insider-buying stocks.

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $3.52.

How much money does AzurRx BioPharma make?

AzurRx BioPharma has a market capitalization of $32.83 million. The company earns $-32,670,000.00 in net income (profit) each year or ($11.50) on an earnings per share basis.

How many employees does AzurRx BioPharma have?

AzurRx BioPharma employs 12 workers across the globe.

What is AzurRx BioPharma's official website?

The official website for AzurRx BioPharma is

Where are AzurRx BioPharma's headquarters?

AzurRx BioPharma is headquartered at 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at (649) 699-7855 or via email at [email protected].com.

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.